Xaar Share Discussion Threads

[dougmachin] 01/10/2021 11:34

They mentioned that it could be becoming a GP stock...
SCSW might be adding it at these values.

[montynj] 01/10/2021 11:27

Best stick to SCSW portfolio stocks..SCSW rarely ever follows up on non portfolio stocks that go wrong

[ny boy] 01/10/2021 11:17

I am staying patient for 140/150p area to take a position, maybe the markets will let me in, if this month prices to be a bit rocky. Waiting game

[dougmachin] 01/10/2021 11:01

Looking about right for a punt at this point Johnny-boy.

[john09] 01/10/2021 10:56

I just can’t figure out the prospects of this one. Feels a bit complicated

I want to figure it out because i remember last time it romped to £13

[dr biotech] 01/10/2021 10:48

He did say he was going to add this to GP3. Will be interesting to see if he does and at what price. Having that “live” on the website would be a really good development.

[john09] 01/10/2021 09:59

Yes case in point - I wouldn’t have touched Heiq and they’ve barely mentioned it since

[iandippie] 01/10/2021 09:57

I think the answer to that is basically stick to the ones scsw is confident enough to put in its own portfolio. They live or die by that, and you can't argue with 500% growth in 6 years.

[dangersimpson2] 01/10/2021 09:51

140p looks like fairly strong support on the chart, and then around 120p if that fails.

[john09] 01/10/2021 09:50

I must confess on XAAR ive read the articles and then i ended u on XAARs website and started watching videos of interviews of Chinese people and not sure i understand what the opportunity is. That’s what’s discouraged me from this one. I dont get it but i know its well backed !

[dr biotech] 01/10/2021 09:46

I’ve taken the hit here. Scsw has given me some decent risers but this has dropped 40% in a few weeks add that to Heiq (-50%) and several others that have performed woefully over the last couple of months (bango/superdry) and I’m wondering whether to keep the faith.

Not a big position here for me, but overall the last few weeks have been the worst since the beginning of the pandemic.

[sickofit] 30/9/2021 14:49

Based on what? Random thoughts?

[northwards] 30/9/2021 11:43

Suspect China supply chain issues are weighing here.

[volsung] 28/9/2021 08:30

Bought a few more at 180.53p
Crucial point chartwise
Hopefully a bounce from here

[ny boy] 24/9/2021 12:33

General equity markets could easily sell off sharply, too much complacency around, wait until the China dominos start to fall when Evergrande defaults, rock period ahead imo, not buying these yet, will see if the market allows me to buy 140-150p area over the coming month

[zho] 16/9/2021 07:24

Simon Thomson in Investors' Chronicle:

The price has since pulled back close to my last entry point (185p) on profit taking which means that Xaar is now rated on an enterprise valuation to cash profit multiple of 9 for 2023, hardly excessive for a recovery stock. I am tweaking my target up slightly from 220p to 230p and continue to rate the shares a buy.



(Search on text to access whole article)

[northwards] 15/9/2021 09:41

Investec raises its target to 280p. https://twitter.com/SCSWSharewatch/status/1437766835718574080?s=20

[dr biotech] 14/9/2021 17:40

Seems the uncertain outlook is to blame. Similar article in sharecast to the one below.




hxxps://www.sharesmagazine.co.uk/news/shares/xaar-sinks-12-on-wider-first-half-loss



Inkjet printing technology specialist Xaar (XAR) fell 12.3% to 190p after posting a deeper first half loss as rising revenue was offset by increased expenses, including higher R&D spending.

This, plus a highly caveated outlook statement, appeared to prompt fears of an eventual profit warning, despite the company sticking with full year guidance for now.

Often a weak first half creates a situation where a company struggles to catch up and is eventually forced to guide full-year expectations lower.

Pre-tax losses for the six months through June amounted to £5.6 million, compared to £4.8 million for the same six month period a year earlier.

Revenue rose 11% to £26.3 million, which Xaar said was in line with its expectations.

3D PRINTING SALE TAKES LONGER THAN EXPECTED

The company said it would announce details of a planned sale of its 3D-printing division soon, while admitting the process had taken longer than expected.

Notwithstanding the proceeds from any sale of this business the company was sitting on net cash of £17.1 million.

‘We are pleased with our continued strong performance which, despite challenging market conditions, demonstrates the success of our strategy and underlying strength of the business,’ chief executive John Mills said.

‘Our foundations remain strong, as we continue to gain new customers and positively re-engage in our core markets.’

‘The Covid-19 pandemic continues to cause disruption for business, however we are determined to minimise interruption to the supply of printheads, and we are well-positioned to withstand further volatility caused by the pandemic.’

[malcolmmm] 14/9/2021 16:21

Its MRCH they are up today I think

[farmergeorge] 14/9/2021 16:17

Malcolmmm, thanks. What's the epic for the Merchants board?

[malcolmmm] 14/9/2021 15:59

Yes just bought a few more, see how they finish today

[investoree] 14/9/2021 15:57

The more of these I buy the lower the price goes, hopefully no bad news in the pipeline.